MCLAUGHLIN JOHN 4
4 · Sonoma Pharmaceuticals, Inc. · Filed Jul 9, 2026
Research Summary
AI-generated summary of this filing
Sonoma (SNOA) Director John McLaughlin Receives 10,000-Share Award
What Happened
John McLaughlin, a director of Sonoma Pharmaceuticals (SNOA), was granted an award of 10,000 derivative shares (options) on July 9, 2026. The filing shows the award as a derivative acquisition with no per-share price or immediate cash value reported — these are equity awards that vest over time rather than a purchase or sale.
Key Details
- Transaction date: 2026-07-09 (filed same day).
- Transaction type: Award/Grant of derivative securities (code A).
- Quantity: 10,000 derivative shares (options). Price: reported as N/A.
- Vesting (Footnote): Options vest one-third on 7/9/2027, one-third on 7/9/2028 and one-third on 7/9/2029, or upon a change of control.
- Purpose (Footnote): Award granted for services performed on the Board of Directors.
- Shares owned after transaction: Not specified in the provided filing.
- Timeliness: Filed on the reporting date (no late filing indicated).
Context
These are granted options (a compensation award) and do not represent immediately realizable cash or stock until vested and exercised. Such director grants are common for board compensation; they differ from open-market purchases (which can signal a bullish bet) or sales (which can be liquidity-driven). The change-of-control clause accelerates vesting if the company is acquired.
Insider Transaction Report
- Award
Stock option (right to buy)
[F2][F1]2026-07-09+10,000→ 30,001 totalExercise: $1.26Exp: 2036-07-09→ Common Stock (10,000 underlying)
Footnotes (2)
- [F1]The options vest one third each on 7/9/2027, 7/9/2028 and 7/9/2029, or upon change of control.
- [F2]The options were awarded and granted to Mr. McLaughlin for services performed on the Board of Directors.